Image via South China Morning Post - Business
Last updated
Gilead Sciences: Ma Activity
Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
The leadership read
Consolidation shifts the leadership question from growth to integration. For Gilead Sciences in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Asia, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: Against a Talent Market Index of 104.6 (Hot) (down 1.9 month-on-month), Asia is at steady (-1pts) on signal share.
Gilead Sciences: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies; 0.2% of MitchelLake's Asia signal flow; 3 tracked across 62 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
Restructuring · Asia
Samsung Biologics →Samsung Biologics unionized workers voted to leave the Samsung Group United Union and form an independent labor union, following months of work-to-rule campaigns and strikes over pay and working conditions.
Geographic Expansion · Asia
Thermo Fisher Scientific →Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Capital Raising · Asia
Legend Biotech →First Beijing Investment Ltd acquired $43.78 million stake (2.3M shares) in Legend Biotech, a cancer cell therapy developer
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Ma Activity · Americas
Biogen →Biogen is relying on drugs acquired through the Apellis deal to offset weak sales of Leqembi (Alzheimer's drug), indicating strategic dependence on M&A to bolster pipeline performance.
Intelligence powered by Autonodal ↗